



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket 044921-5029-01		Application No. 09/960,706	
				Applicants: William E. Munger <i>et al.</i>		Page 1 of 1	
PTO Form 1449				Filing Date: September 24, 2001		Group Art Unit: 1631	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<i>MWY</i>	aa	2003/0134324 A1	07/17/2003	Munger <i>et al.</i>	435	7.1	06/05/2001
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>MWY</i>	ab	Elsasser-Beile <i>et al.</i> , Comparison of the Activation Status of Tumor Infiltrating and Peripheral Lymphocytes of Patients with Adenocarcinomas and Benign Hyperplasia of the Prostate, (2000) The Prostate, 45:1-7					
<i>MWY</i>	ac	Shidaifat <i>et al.</i> , Gossypol Arrests Human Benign Prostatic Hyperplastic Cell Growth at G0/G1 Phase of the Cell Cycle, (1997) Anticancer Res. 17:1003-1010					
Examiner			Date Considered				
<i>MWY Munger</i>			3/22/05				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Please type a plus sign (+) inside this box →

MAR 07 2005

PTEN & TRADEMARK OFFICE
U.S. PATENT AND TRADEMARK OFFICE

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/960,706
				Filing Date	9/24/2001
				First Named Inventor	William MUNGER
				Group Art Unit	1631
				Examiner Name	Moran, M.
Sheet	1	of	1	Attorney Docket Number	44921-5029-01-US

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MAM		5,763,429		Bishop et al.	6/9/1998	
MAM		5,882,884		An et al.	3/16/1999	

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
							T ₆


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
MAM		Bubendorf, L et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. (1999) Cancer Research 59:803-806.					
MAM		Bubendorf, L et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. (1999) J. Nat. Cancer Inst. 91(20):1758-1764.					


Examiner Signature	<i>MA Moran</i>	Date Considered	3/22/05
--------------------	-----------------	-----------------	---------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.







Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number 09/960,706

Filing Date 9/24/2001

First Named Inventor William MUNGER

Group Art Unit 1631

Examiner Name Moran, M.

Attorney Docket Number 44921-5029-01-US TECH CENTER 1600/2900

RECEIVED

AUG 23 2002

2002

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		5,783,429		Bishop et al.	6/9/1998
		5,882,864		An et al.	3/16/1999

FOREIGN PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Bubendorf, L et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. (1999) Cancer Research 59:803-806.			
		Bubendorf, L et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. (1999) J. Nat. Cancer Inst. 91(20):1758-1764.			

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.